問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taichung Veterans General Hospital

Recruiting

List

640Cases

2021-02-25 - 2024-06-05

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2015-10-01 - 2020-06-30

Phase III

Completed
A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer

  • Condition/Disease

    Urothelial Bladder Cancer

  • Test Drug

    MEDI4736; Tremelimumab

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2023-02-01 - 2026-12-31

Phase I

Active
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)

  • Condition/Disease

    Advanced or Metastatic NSCLC

  • Test Drug

    凍晶注射劑 注射劑 注射劑 注射劑 注射劑

Participate Sites
7Sites

Recruiting7Sites

2022-01-01 - 2031-02-27

Phase III

Active
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Durvalumab Oleclumab Monalizumab

Participate Sites
8Sites

Recruiting8Sites

2018-09-28 - 2026-12-31

Phase III

Active
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

  • Condition/Disease

    Muscle-Invasive Bladder Cancer

  • Test Drug

    Durvalumab

Participate Sites
8Sites

Recruiting6Sites

Terminated1Sites

2023-07-01 - 2026-09-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-11-01 - 2031-06-30

Phase III

Not yet recruiting
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

  • Condition/Disease

    Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

  • Test Drug

    injection

Participate Sites
8Sites

Recruiting8Sites

2022-03-31 - 2027-12-31

Phase III

Active
A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-3)

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    靜脈點滴注射劑 靜脈點滴注射劑

Participate Sites
6Sites

Recruiting6Sites

2020-09-15 - 2025-12-31

Phase III

Completed
A randomized, double-blind, double-dummy, parallel grouping, multi-center 24 to 52-week variable length trial designed to evaluate Budesonide, Glycopyrronium, and Formoterol Fumarate metered-dose inhalers (MDI) relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pressure MDI, the efficacy and safety of adult and adolescent participants with poor asthma control (KALOS)

  • Condition/Disease

    Adults and adolescents with poor asthma control

  • Test Drug

    BGF MDI

Participate Sites
12Sites

Recruiting12Sites

2018-11-30 - 2025-12-31

Phase III

Active
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)

  • Condition/Disease

    Locoregional Hepatocellular Carcinoma

  • Test Drug

    DURVALUMAB (IMFINZI, MEDI4736)

Participate Sites
10Sites

Recruiting9Sites

林錫銘
Linkou Chang Gung Medical Foundation

Digestive System Department

1 10 11 12 13 14 64
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB